Abstract Treatment with immune checkpoint blockade (CPB) therapies often leads to
prolonged responses in patients with metastatic melanoma, but the common mechanisms of …

During cancer therapy, tumor heterogeneity can drive the evolution of multiple tumor
subclones harboring unique resistance mechanisms in an individual patient 1 , 2 – 3 . Previous …

Clinically relevant subtypes exist for pancreatic ductal adenocarcinoma (PDAC), but molecular
characterization is not yet standard in clinical care. We implemented a biopsy protocol to …

ATP-competitive FGFR inhibitors (BGJ398, Debio 1347) show efficacy in FGFR2 -altered
ICC; however, acquired FGFR2 kinase domain mutations cause drug resistance and tumor …

Purpose: ctDNA offers a promising, noninvasive approach to monitor therapeutic efficacy in
real-time. We explored whether the quantitative percent change in ctDNA early after therapy …

Purpose: Although patients with advanced-stage non–small cell lung cancers (NSCLC)
harboring MET exon 14 skipping mutations (METex14) often benefit from MET tyrosine kinase …

Clonal heterogeneity associated with acquired resistance presents a critical therapeutic
challenge. Whole-exome sequencing of paired tumor biopsies and targeted sequencing of cell-…

PURPOSE This study was designed to assess the ability of perioperative circulating tumor
DNA (ctDNA) to predict surgical outcome and recurrence following neoadjuvant …

Purpose Third-generation epidermal growth factor receptor (EGFR) inhibitors like nazartinib
are active against EGFR mutation–positive lung cancers with T790M-mediated acquired …

Background: Approximately 50% of melanomas harbor BRAF mutations. Treatment with
BRAF +/− MEK inhibition is associated with favorable changes in the tumor microenvironment …